FHLC
Fidelity MSCI Health Care Index ETF
The Fidelity MSCI Health Care Index ETF is an exchange-traded fund incorporated in the USA. The ETF seeks to provide investment returns that correspond, before fees and expenses, generally to the performance of the MSCI USA IMI Health Care Index.
US
EQUITY
Passive
MANAGEMENT STYLE
$ 2.8 B
ASSETS UNDER MGMT
8 bp
EXPENSES
Fund Basics
| Inception date | Oct 21, 2013 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| ELI LILLY & CO | 12.5 % |
| JOHNSON & JOHNSON | 8.8 % |
| ABBVIE INC | 5.9 % |
| UNITEDHEALTH GROUP INC | 5.4 % |
| MERCK & CO. INC. | 4.5 % |
| AMGEN INC | 2.9 % |
| THERMO FISHER SCIENTIFIC INC | 2.8 % |
| GILEAD SCIENCES INC | 2.6 % |
| INTUITIVE SURGICAL INC | 2.6 % |
| ABBOTT LABORATORIES | 2.5 % |
Constituent Breakdown
| Number of holdings | 341 |
| Herfindahl-Hirschman Index | 397 |
| Wgt avg mkt cap (mns) | $272,497 |
| Large cap (>$10bn) | 90.5% |
| Mid cap ($2-10bn) | 6.0% |
| Small cap (<$2bn) | 1.8% |
| Developed mkts. | 98.6% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 95.8 % |
 |
IRELAND | 2.3 % |
Historical Performance
Standardized Performance (as of 04/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -5.2% | 6.8% | 3.2% | 3.6% | 2.8% | 7.9% | -- | 8.6% |
| Dividend Yield | 0.0% | 1.3% | 1.4% | 1.4% | 1.4% | 1.6% | -- | 1.6% |
| Total Returns | -5.2% | 8.0% | 4.6% | 5.0% | 4.2% | 9.5% | -- | 10.2% | Ann. Volatility | 15.3% | 15.7% | 15.2% | 13.9% | 14.9% | 16.8% | -- | 16.8% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.62 | 24% |
| MSCI EAFE | 0.61 | 32% |
| MSCI Emg Mkts | 0.32 | 15% |
Liquidity Measures
| Avg. volume (000) | 205 |
| ADV traded (mns) | $14 |
| Turnover | 0.5% |
| Avg. Bid/Ask (% of price) | 0.03% |
Technical Indicators
| 30d moving avg. (EMA) | $70.58 |
| Relative strength (RSI) | 43 |
| MACD/Signal | -0.35/-0.37 |
| Bollinger Bands (Upper/Lower) | $72.06/$68.85 |
| Short interest (% of AUM) | 0.1% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. FHLC |
Expenses vs. FHLC |
ALTAR Score™ vs. FHLC |
|---|---|---|---|---|
| VHT | Vanguard Health Care ETF | 96.3% | +1 bp | -0.2% |
| IYH | iShares U.S. Healthcare ETF | 86.7% | +32 bp | +0.5% |
| XLV | Health Care Select Sector SPDR | 84.7% | 0 bp | +1.3% |
| IXJ | iShares Global Healthcare ETF | 69.8% | +34 bp | +1.1% |
| HRTS | Tema Heart & Health ETF | 52.0% | +67 bp | -2.6% |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 49.5% | +32 bp | +1.3% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 43.9% | +52 bp | +1.7% |
| GDOC | Goldman Sachs Future Health Care Equity ETF | 40.1% | +67 bp | -4.5% |
| MEDX | Horizon Kinetics Medical ETF | 38.2% | +77 bp | -4.5% |
| PINK | Simplify Health Care ETF | 37.1% | +42 bp | -4.6% |
Risk and Returns: FHLC vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 5/17/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
6.0%
ALTAR SCORE™
61st
PERCENTILE
OVERWEIGHT
ETFRC RATING
There are 1,207 funds in the US Equity category with an average
ALTAR Score™ of 5.4% and a standard deviation
of 2.1%. FHLC's ALTAR Score™ is approximately 0.3 standard
deviations above the category average. This places FHLC in the 61st percentile
among funds in the category.
Sell-Side Consensus
$86.62
PRICE TARGET
+23.8%
UPSIDE